EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes

BACKGROUND: Approximately 3–5% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) harbor exon 18 mutations. The appropriate treatment for such patients has not been clarified. The aim of this study was to investigate the response of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haiyan, Yang, Guangjian, Li, Weihua, Li, Junling, Hao, Xuezhi, Xing, Puyuan, Yang, Yaning, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445032/
https://www.ncbi.nlm.nih.gov/pubmed/34540680
http://dx.doi.org/10.3389/fonc.2021.713483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445032/
https://www.ncbi.nlm.nih.gov/pubmed/34540680
http://dx.doi.org/10.3389/fonc.2021.713483

Ejemplares similares